###begin article-title 0
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vitro</italic>
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
In Vitro Identification and Characterization of CD133pos Cancer Stem-Like Cells in Anaplastic Thyroid Carcinoma Cell Lines
###end article-title 0
###begin p 1
Conceived and designed the experiments: GZ PR VR AC GP AG CG. Performed the experiments: GZ PR AB EC LR AC MZ GP AG CG. Analyzed the data: GZ PR EC VR AC MCA AG CG. Contributed reagents/materials/analysis tools: GZ AB GP AG CG. Wrote the paper: GZ AC MCA AG CG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Recent publications suggest that neoplastic initiation and growth are dependent on a small subset of cells, termed cancer stem cells (CSCs). Anaplastic Thyroid Carcinoma (ATC) is a very aggressive solid tumor with poor prognosis, characterized by high dedifferentiation. The existence of CSCs might account for the heterogeneity of ATC lesions. CD133 has been identified as a stem cell marker for normal and cancerous tissues, although its biological function remains unknown.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 105 108 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 445 448 441 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 552 555 548 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 579 582 575 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 714 717 710 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 849 852 845 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 879 882 875 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 1072 1075 1068 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 1104 1107 1100 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
ATC cell lines ARO, KAT-4, KAT-18 and FRO were analyzed for CD133 expression. Flow cytometry showed CD133pos cells only in ARO and KAT-4 (64+/-9% and 57+/-12%, respectively). These data were confirmed by qRT-PCR and immunocytochemistry. ARO and KAT-4 were also positive for fetal marker oncofetal fibronectin and negative for thyrocyte-specific differentiating markers thyroglobulin, thyroperoxidase and sodium/iodide symporter. Sorted ARO/CD133pos cells exhibited higher proliferation, self-renewal, colony-forming ability in comparison with ARO/CD133neg. Furthermore, ARO/CD133pos showed levels of thyroid transcription factor TTF-1 similar to the fetal thyroid cell line TAD-2, while the expression in ARO/CD133neg was negligible. The expression of the stem cell marker OCT-4 detected by RT-PCR and flow cytometry was markedly higher in ARO/CD133pos in comparison to ARO/CD133neg cells. The stem cell markers c-KIT and THY-1 were negative. Sensitivity to chemotherapy agents was investigated, showing remarkable resistance to chemotherapy-induced apoptosis in ARO/CD133pos when compared with ARO/CD133neg cells.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 17 20 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 55 58 55 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 377 385 377 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
We describe CD133pos cells in ATC cell lines. ARO/CD133pos cells exhibit stem cell-like features - such as high proliferation, self-renewal ability, expression of OCT-4 - and are characterized by higher resistance to chemotherapy. The simultaneous positivity for thyroid specific factor TTF-1 and onfFN suggest they might represent putative thyroid cancer stem-like cells. Our in vitro findings might provide new insights for novel therapeutic approaches.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 289 292 289 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-1">[1]</xref>
###xml 140 148 <span type="species:ncbi:9606">Patients</span>
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive endocrine tumors with morphological features of undifferentiated neoplasm. Patients with ATC have a poor prognosis with a mean survival time of 2-6 months. Surgery, radiotherapy and chemotherapy do not improve survival rate [1].
###end p 9
###begin p 10
###xml 67 70 67 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Thomas1">[2]</xref>
###xml 244 247 240 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Thomas1">[2]</xref>
###xml 248 251 244 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Lin1">[4]</xref>
###xml 46 51 <span type="species:ncbi:9606">human</span>
Recently, adult stem cells were identified in human thyroid glands [2]. These cells express several specific markers, such as the nuclear transcription factor OCT-4 (also known as OCT-3, OCT-3/4) and the endodermal markers GATA-4 and HNF4alpha [2]-[4].
###end p 10
###begin p 11
###xml 157 160 157 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Reya1">[5]</xref>
###xml 215 218 215 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Lapidot1">[6]</xref>
###xml 233 236 233 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Singh1">[7]</xref>
###xml 245 248 245 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Ponti1">[8]</xref>
###xml 259 262 259 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Patrawala1">[9]</xref>
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Houghton1">[10]</xref>
###xml 283 287 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Kim1">[11]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-OBrien1">[12]</xref>
###xml 481 485 481 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Bjerkvig1">[13]</xref>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Ma1">[14]</xref>
###xml 660 664 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Baguley1">[15]</xref>
###xml 1003 1007 1003 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Mitsutake1">[16]</xref>
###xml 1189 1193 1189 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Takano1">[17]</xref>
A link between stem and cancer cells has been suggested in various tissues where cancer cells are supposed to derive from immature progenitors or stem cells [5]. Cancer stem cells (CSCs) have been found in leukemia [6], glioblastoma [7], breast [8], prostate [9], gastric [10], lung [11], and colon [12] cancer. These cells, which represent only a small population within the bulk of the tumor, possess the simultaneous ability to self-renew and differentiate into other cytotypes [13]. The stem-like phenotype has proved to be capable of resisting conventional therapies, thus leading to disease relapse even when the primary lesion has been eradicated [14], [15]. To date, however, no studies have definitely indicated that stem cells are responsible for thyroid carcinogenesis. However, the rarity and rapid growth pattern of ATC resembles the nature of stem cells. Only one study has described a very small population, termed side population, enriched for stem cells among thyroid cancer cell lines [16]. In addition, the hypothesis of fetal cell carcinogenesis, in which cancer cells are derived from the remnants of fetal thyroid cells instead of adult thyrocytes, has been proposed [17].
###end p 11
###begin p 12
###xml 194 195 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Yin1">[18]</xref>
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Miraglia1">[19]</xref>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Seigel1">[20]</xref>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Mizrak1">[21]</xref>
###xml 435 438 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 514 522 514 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Ma1">[14]</xref>
###xml 710 714 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Nichols1">[22]</xref>
###xml 842 846 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Zangrossi1">[23]</xref>
###xml 848 852 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Liedtke1">[24]</xref>
###xml 71 76 <span type="species:ncbi:9606">Human</span>
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
###xml 229 234 <span type="species:ncbi:9606">human</span>
###xml 373 378 <span type="species:ncbi:9606">human</span>
###xml 643 648 <span type="species:ncbi:9606">human</span>
Several markers have been identified for the characterization of CSCs. Human CD133, a highly conserved antigen homologue of mouse Prominin-1, was originally identified in a subpopulation of CD34+ hematopoietic cells derived from human fetal liver and bone marrow [18]-[19]. CD133 has been used for the identification and isolation of a putative CSC population from several human cancers [20], [21]. In addition, the expression of CD133pos CSCs in hepatocellular carcinoma (HCC) was shown to confer chemoresistance in vitro[14]. However, its biological function remains unknown. The transcription factor OCT-4 is considered a main regulator of human embryonic stem cell pluripotency and self-renewal capacities [22]. Interestingly, these stem-cell properties are attributed to OCT-4A, a splice variant of the OCT-4 gene located in the nucleus [23], [24].
###end p 12
###begin p 13
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 264 272 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 338 341 338 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 376 379 376 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 443 446 443 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 108 113 <span type="species:ncbi:9606">human</span>
The aim of the present study was to investigate the expression of putative stem cell markers in established human ATC cell lines, such as ARO, KAT-4, KAT-18 and FRO. We identified CD133pos cells in ARO and KAT-4 cell lines. This subset was characterized by higher in-vitro proliferation, self-renewal and colony forming ability. ARO/CD133pos were more resistant than ARO/CD133neg cells to chemotherapy-induced apoptosis. In addition, ARO/CD133pos cells expressed the thyroblast specific transcription factor TTF-1 and the stem cell marker OCT-4, whereas they were negative for the stem cell markers c-Kit and THY-1.
###end p 13
###begin title 14
Materials and Methods
###end title 14
###begin title 15
Cell lines and culture conditions
###end title 15
###begin p 16
###xml 509 513 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Hamburger1">[25]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 245 251 <span type="species:ncbi:9913">bovine</span>
Human ATC cell lines ARO, KAT-4, KAT-18 and FRO were kindly provided by Prof. A. Fusco, University of Naples, Italy. During expansion phase and for self-renewal assay cells were cultured in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS). For all other experiments, cells were cultured in RPMI1640 serum free medium (SFM), supplemented with basic Fibroblast Growth Factor (bFGF, 20 ng/ml; Sigma-Aldrich, St. Louis, MO, USA) and Epidermal Growth Factor (EGF, 20 ng/ml; Sigma-Aldrich) [25].
###end p 16
###begin title 17
Flow Cytometry
###end title 17
###begin p 18
###xml 361 366 <span type="species:ncbi:10090">mouse</span>
###xml 378 383 <span type="species:ncbi:9606">human</span>
###xml 512 517 <span type="species:ncbi:10090">mouse</span>
###xml 528 533 <span type="species:ncbi:9606">human</span>
###xml 544 549 <span type="species:ncbi:10090">mouse</span>
###xml 560 565 <span type="species:ncbi:9606">human</span>
###xml 769 773 <span type="species:ncbi:9925">goat</span>
###xml 779 784 <span type="species:ncbi:10090">mouse</span>
###xml 1024 1029 <span type="species:ncbi:10090">mouse</span>
###xml 1041 1046 <span type="species:ncbi:9606">human</span>
###xml 1214 1218 <span type="species:ncbi:9925">goat</span>
###xml 1224 1229 <span type="species:ncbi:10090">mouse</span>
The expression of stem cell markers CD133, OCT-4, c-Kit and THY-1 was evaluated by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA, USA). For CD133 analysis, cells were first treated with FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and then incubated in the dark at 4degreesC for 10 minutes with phycoerythrin (PE)-conjugated mouse IgG2b anti human CD133/2 (clone 293C3, Miltenyi Biotec). For co-staining with c-Kit and THY-1, cells were subsequently incubated with monoclonal mouse IgG1 anti-human c-KIT and mouse IgG1 anti-human THY-1 antibodies (Chemicon International, Temecula, Ca, USA) at 4degreesC for 30 minutes. Cells were washed twice with PBS and then incubated with fluorescein isothiocyanate (FITC)-conjugated polyclonal goat anti-mouse at 4degreesC for 30 minutes. For staining with OCT-4, cells were fixed and permeabilized with Cytofix-Cytoperm kit (BD Pharmingen, San Diego, Ca, USA) according to the manufacturer's instructions. Cells were then incubated with monoclonal mouse IgG2b anti-human OCT-3/4 (Santa Cruz Biotechnology, Santa Cruz, Ca, USA) at 4degreesC for 30 minutes, washed twice with PBS and incubated with phycoerythrin (PE)-conjugated polyclonal goat anti-mouse at 4degreesC for 30 minutes. The primary antibody recognizes the OCT-4A isoform of the protein (aa 1-134).
###end p 18
###begin p 19
###xml 239 245 <span type="species:ncbi:9986">rabbit</span>
###xml 422 426 <span type="species:ncbi:9925">goat</span>
###xml 432 438 <span type="species:ncbi:9986">rabbit</span>
Apoptosis was evaluated by caspase 3 assay. Cells were first fixed and permeabilized with Cytofix-Cytoperm kit (BD Pharmingen, San Diego, Ca, USA) according to the manufacturer's instructions. Cells were then incubated with monoclonal IgG rabbit anti-Active Caspase 3 (BD Pharmingen) at room temperature for 20 minutes, washed twice with PBS and then incubated with fluorescein isothiocyanate (FITC)-conjugated polyclonal goat anti-rabbit IgG (Santa Cruz Biotechnology) at room temperature for 20 minutes.
###end p 19
###begin p 20
Data were analyzed with CELLQuest Pro software (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Gating was implemented based on negative control staining profiles.
###end p 20
###begin title 21
Immunocytochemistry
###end title 21
###begin p 22
###xml 188 189 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 190 191 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 404 409 <span type="species:ncbi:10090">mouse</span>
###xml 415 420 <span type="species:ncbi:9606">human</span>
###xml 618 629 <span type="species:ncbi:3704">horseradish</span>
ARO and KAT-4 cell lines were plated in chamber slides (Lab-Tek, Nunc, Inc. Naperville, USA), allowed to attach for 48 hours and then used for immunocytochemistry. Cells were fixed in 3% H2O2 in methanol for 10 minutes at room temperature, then washed twice in PBS, blocked with 3% BSA and permeabilized with PBS containing 0.1% Triton X-100 for 10 minutes at room temperature. Cells were incubated with mouse anti-human CD133 (IgG1, clone AC133, Miltenyi Biotec) in blocking buffer for 1 hour at room temperature, then rinsed with PBS. Expression was detected using secondary biotinylated antibodies and streptavidin/horseradish peroxidase. Chromogen 3-amino-9-ethylcarbazole (AEC) substrate was used and slides were counterstained with hematoxylin.
###end p 22
###begin title 23
###xml 20 23 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
Sorting of ARO/CD133pos cells
###end title 23
###begin p 24
###xml 296 301 <span type="species:ncbi:9606">human</span>
ARO cells were trypsinized and labeled with primary CD133-Biotin and Biotin-Microbeads (Indirect CD133 cell Isolation Kit, Miltenyi Biotec), according to the manufacturer's instructions. After magnetic sorting, cell purity was evaluated by flow cytometry using phycoerythrin (PE)-conjugated anti-human CD133/2 (clone 293C3, Miltenyi Biotec).
###end p 24
###begin title 25
Isolation of total RNA, RT-PCR and qRT-PCR
###end title 25
###begin p 26
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 114 117 114 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 688 692 680 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Takano2">[26]</xref>
###xml 693 697 685 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Liu1">[27]</xref>
###xml 813 814 793 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1258 1286 1198 1226 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTTCGAGTACCAGGTTGATGCC-3&#8242;</named-content>
###xml 1291 1319 1231 1259 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGTGGTTTCAGTGAAGGTGGAA-3&#8242;</named-content>
###xml 1348 1377 1282 1311 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGTGTCCAACGTGTTCTCCACAG-3&#8242;</named-content>
###xml 1382 1409 1316 1343 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AAGACGTGGCTGTTCTCCCAC-3&#8242;</named-content>
###xml 1438 1464 1366 1392 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTATGGCCTCAAGTTCCTCT-3&#8242;</named-content>
###xml 1469 1495 1397 1423 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCGTGGCTACAATGTACTGC-3&#8242;</named-content>
###xml 1526 1552 1448 1474 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCTTCATGGACCAGAGATCT-3&#8242;</named-content>
###xml 1557 1582 1479 1504 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TATGGTCTTGGCTATGCCT-3&#8242;</named-content>
###xml 1613 1639 1529 1555 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGCCCTCATTTCACCAGGCC-3&#8242;</named-content>
###xml 1644 1670 1560 1586 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGGGACTCCTCCGGGTTTTG-3&#8242;</named-content>
###xml 1706 1741 1613 1648 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATGACCCAGATGACCCAGATCATGTTTG-3&#8242;</named-content>
###xml 1746 1771 1653 1678 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGGCTGGAAGAGTGCCTCA-3&#8242;</named-content>
###xml 2583 2609 2462 2488 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGACTTCGAGCAAGAGATGG-3&#8242;</named-content>
###xml 2615 2641 2494 2520 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGCACTGTGTTGGCGTACAG-3&#8242;</named-content>
###xml 2643 2647 2522 2526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Hellemans1">[28]</xref>
Total RNA was extracted and purified from cultured KAT-4, KAT-18, FRO and ARO (unsorted, sorted CD133neg and CD133pos) cell lines using RNeasy Mini Kit (Qiagen, Milan, Italy), including a digestion step with DNase I set. RNA quantity and quality were assessed by UV spectrophotometry. 2 microg total RNA were reverse transcribed in a volume of 20 microl with Oligo dT primers (Applied Biosystems, Darmstad, Germany) and Stratascript RT (Stratagene, Amsterdam, Netherland), according to the manufacturer's protocol. Thyroglobulin (Tg), thyroperoxidase (TPO), sodium/iodide symporter (NIS), oncofetal fibronectin (onfFN) and OCT-4 expression was analyzed by polymerase chain reaction (PCR) [26]-[27]. 1 microl complementary DNA was added to 50 microl reaction containing 5 microl 10x reaction buffer, 50 mmol/L MgCl2, 1 microl dNTPs, 50 pmol sense and antisense primers and 0.5 U Taq Gold DNA polymerase. Reactions were carried out at 95degreesC for 10 minutes; 35 cycles at 95degreesC for 45 seconds, 55degreesC for 45 seconds (primer specific) and 72degreesC for 45 seconds, followed by an extension at 72degreesC for 7 minutes and termination at 4degreesC. Primer pair sequences, cDNA fragment sizes and annealing temperatures were as follows: Tg (762 bp): 5'-CTTCGAGTACCAGGTTGATGCC-3' and 5'-GGTGGTTTCAGTGAAGGTGGAA-3' (55degreesC), TPO (593 bp): 5'-TGTGTCCAACGTGTTCTCCACAG-3' and 5'-AAGACGTGGCTGTTCTCCCAC-3' (55degreesC), NIS (179 bp): 5'-CTATGGCCTCAAGTTCCTCT-3' and 5'-TCGTGGCTACAATGTACTGC-3' (57degreesC), onfFN (215 bp): 5'-TCTTCATGGACCAGAGATCT-3' and 5'-TATGGTCTTGGCTATGCCT-3' (55degreesC), OCT-4 (456 bp): 5'-AGCCCTCATTTCACCAGGCC-3' and 5'-TGGGACTCCTCCGGGTTTTG-3' (63degreesC), beta-actin (439 bp): 5'-GATGACCCAGATGACCCAGATCATGTTTG-3' and 5'-AGGCTGGAAGAGTGCCTCA-3' (55degreesC). For OCT-4 analysis, nTERA2 cDNA (positive control) was kindly provided by Dr. S. Liedtke, University of Dusseldorf, Germany. For onfFN and TTF-1, TAD-2 cDNA was used as positive control. CD133 and TTF-1 expression was analyzed by real-time quantitative PCR (qRT-PCR) in individual samples. Total 2 microg were used to measure mRNA levels relative to beta-actin mRNA expression. PCR primers and probes were purchased from Qiagen (Quantitect Primer Prominin1 and TTF1). All reactions were performed in a final volume of 20 microl with 2 microl cDNA template using a LightCycler (Roche Diagnostics GmbH, Germany). Data analysis was performed with qBASE Browser which employs a Delta-Ct relative quantification model with PCR efficiency correction and single reference gene normalization (beta-actin: 5'-GGACTTCGAGCAAGAGATGG-3', and 5'-AGCACTGTGTTGGCGTACAG-3') [28].
###end p 26
###begin title 27
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vitro</italic>
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
In Vitro Culture and Cell Proliferation Assay of ARO/CD133pos cells
###end title 27
###begin p 28
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 43 46 43 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
After isolation, ARO/CD133pos and ARO/CD133neg cells were cultured immediately in SFM supplemented with bFGF and EGF in an atmosphere of 5% CO2 at 37degreesC.
###end p 28
###begin p 29
###xml 221 224 221 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 238 241 238 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
Cell proliferation was assessed by colorimetric assay using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and BrdU (colorimetric) kit (Roche Diagnostics GmbH, Germany). For MTT assay, sorted ARO/CD133pos and ARO/CD133neg cells were plated in a 96-well plate in 100 microl SFM/well and cultured up to 72 hours. Cells were incubated for 4 hours at 37degreesC with MTT; after incubation, medium was removed and cells were treated with DMSO for 5 minutes. Viability was evaluated by UV absorption spectrum at 550 nm with Microplate Reader Model 550 (Bio-Rad, Richmond, CA, USA).
###end p 29
###begin p 30
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
For BrdU assay, sorted ARO/CD133pos and ARO/CD133neg were plated in a 96-well plate in 100 microl SFM/well and cultured up to 144 hours. Viability was evaluated by UV absorption spectrum at 450 nm with Microplate Reader Model 550 (Bio-Rad, Richmond, CA, USA).
###end p 30
###begin title 31
###xml 31 34 31 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
Self-Renewal Assay of ARO/CD133pos cells
###end title 31
###begin p 32
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
Sorted ARO/CD133pos cells were cultured in RPMI 1640 supplemented with 10% FBS. CD133 expression was detected by flow cytometry on days 0, 4, 8 and 11. At the same time points apoptosis was assessed by Annexin V-FITC Apoptosis Detection Kit (BD Pharmingen, San Diego, Ca, USA) following the manufacturer's instructions.
###end p 32
###begin title 33
###xml 35 38 35 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
Colony formation assay of ARO/CD133pos cells
###end title 33
###begin p 34
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 33 36 33 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
Sorted ARO/CD133pos and ARO/CD133neg cells were cultured in 6-well plates in methylcellulose SFM (HSC-CFU basic medium, Miltenyi Biotec). Plates were maintained at 37degreesC in a humidified incubator for 2 weeks. The number of colonies was assessed by microscopic counting.
###end p 34
###begin title 35
Chemotherapy agents
###end title 35
###begin p 36
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 22 25 22 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 330 333 318 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 343 346 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
ARO/CD133pos and CD133neg cells were cultured in SFM supplemented with bFGF (20 ng/ml) and EGF (20 ng/ml) with or without cisplatin (5, 10, 15 and 20 microM; Pharma, Austria), doxorubicin (0.5, 1, 1.5 and 2 microM; Ebewe Pharma, Austria), etoposide (10, 30, 100 microM; Teva Pharma, Netherland). The percentage of viable ARO/CD133pos and CD133neg cells was evaluated at 24, 48 and 72 hours by MTT assay and at 48, 96 and 120 hours by BrdU assay.
###end p 36
###begin p 37
###xml 35 38 35 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 48 51 48 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
For apoptosis evaluation, ARO/CD133pos and CD133neg cells were cultured in 6-well plates and treated with the highest concentration of each drug (20 microM cisplatin, 2 microM doxorubicin and 100 microM etoposide) up to 120 hours. Apoptosis evaluation (caspase 3 assay) was assessed by flow citometry as described above.
###end p 37
###begin title 38
Statistical analysis
###end title 38
###begin p 39
Statistical analysis was performed with SPSS v. 11 software for Windows. Data are expressed as mean+/-SD. Statistical comparisons were based on nonparametric tests and statistical significance was defined at p<0.05. For experiments with chemoterapics, differences in viability of ATC cell lines were calculated with the Mann-Whitney test; p for trend with different drug concentrations was calculated with the W of Kendall test.
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
Identification of CD133pos cells in ATC cell lines
###end title 41
###begin p 42
###xml 130 136 130 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g001">Fig 1A</xref>
###xml 282 289 278 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g001">Fig. 1B</xref>
###xml 297 300 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 439 446 435 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g001">Fig. 1C</xref>
###xml 541 545 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Takano2">[26]</xref>
###xml 624 628 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Liu1">[27]</xref>
###xml 630 643 626 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g002">Fig. 2A and B</xref>
In order to identify CSCs in ATC cell lines, we analyzed the expression of CD133 by flow cytometry in ARO, KAT-4, KAT-18 and FRO (Fig 1A). ARO and KAT-4 showed a mean positivity of 64+/-9% and 57+/-12%, respectively; KAT-18 and FRO were negative. Results were confirmed by qRT-PCR (Fig. 1B). CD133pos cells in ARO cell lines were characterized by cytoplasmatic and polarized localization of the antigen on the apical surface of the cells (Fig. 1C). The undifferentiated status of ATC cell lines was confirmed in PCR by the presence of onfFN [26] and the absence of thyrocyte-specific differentiating markers Tg, TPO and NIS [27] (Fig. 2A and B).
###end p 42
###begin title 43
Expression of CD133 in ATC cell lines.
###end title 43
###begin p 44
(A) Flow cytometry analysis of CD133 in ARO, KAT-4, KAT-18, and FRO cell lines. Black lines represent positive staining for CD133, grey lines show negative control with matched isotype antibody. Data are representative of three independent experiments. (B) Analysis of CD133 expression in ATC cell lines by qRT-PCR. Data are represented as fold change (relative scale), considering KAT-18 = 1. (C) Immunocytochemistry of CD133 in ARO cell line. Arrows indicate apical and polarized localization of CD133 (20x magnification).
###end p 44
###begin title 45
Undifferentiated status of ATC cell lines.
###end title 45
###begin p 46
Expression of thyroid specific genes (Tg, TPO, NIS) (A) and fetal marker onfFN (B) in ARO, KAT-4 and normal thyroid by RT-PCR. TAD-2 cell line was used as positive control for onfFN mRNA. beta-actin was used as internal control in both experiments. bp = base pairs.
###end p 46
###begin title 47
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
Cell culture of sorted ARO/CD133pos cells
###end title 47
###begin p 48
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 118 125 118 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g003">Fig. 3A</xref>
###xml 154 157 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 287 290 287 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 436 439 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 479 486 479 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g003">Fig. 3B</xref>
Cluster-forming efficiency of sorted ARO/CD133pos cells was evaluated by FACS analysis, showing 90% CD133 positivity (Fig. 3A). After isolation, ARO/CD133pos cells, cultured in SFM supplemented with bFGF and EGF, grew as single, non-adherent, spherical cells. After a few days, ARO/CD133pos cells started to form clusters which progressively increased in number and size, although they did not form follicles. On the contrary, ARO/CD133neg cells scarcely aggregated in clusters (Fig. 3B).
###end p 48
###begin title 49
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
Cluster-forming efficiency of sorted ARO/CD133pos cells.
###end title 49
###begin p 50
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 128 131 128 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 145 148 145 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 190 193 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
(A) Purity of ARO/CD133pos cells after magnetic cell sorting assessed by flow cytometry. (B) Characteristics of sorted ARO/CD133pos and ARO/CD133neg on days 0, 3 and 10 of culture. ARO/CD133pos cells formed clusters which increased in size overtime.
###end p 50
###begin title 51
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 88 91 88 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
In vitro cell proliferation assay, self-renewal and colony-forming capacity of ARO/CD133pos cells
###end title 51
###begin p 52
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 241 254 239 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g004">Fig. 4A and B</xref>
###xml 388 391 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 432 435 430 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 492 499 490 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g004">Fig. 4C</xref>
###xml 531 534 529 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 828 831 826 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 938 941 936 939 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 955 958 953 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 1034 1037 1032 1035 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 1065 1068 1063 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 1094 1097 1092 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 1169 1183 1167 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g004">Fig. 4D and 4E</xref>
Proliferation was evaluated by MTT and BrdU assay. ARO/CD133pos cells showed in vitro increased proliferation in comparison to ARO/CD133neg cells with both MTT at 48-72 hours and BrdU at 72-144 hours (p = 0.028 and p</=0.001, respectively) (Fig. 4A and B). As regards caspase 3, flow cytometry showed spontaneous apoptosis in SFM, which ranged after 144 hours from 0.5 to 2% for ARO/CD133pos cells and from 3.4 to 8.8% for ARO/CD133neg cells (data not shown). Self renewal was also assessed (Fig. 4C). CD133 expression on ARO/CD133pos cells initially decreased from 90% on day 0 to 46% on day 8, and maintained a steady state until day 11. The decrease in CD133 expression overtime was not caused by cell death (<2%, data not shown). Instead, cell proliferation continued for the entire culture period, suggesting that ARO/CD133pos cells are characterized by asymmetrical division ability (i.e. production of two daughter cells, one CD133pos and one CD133neg). Colony-forming assay confirmed the high self-renewal ability of ARO/CD133pos, in comparison to ARO/CD133neg cells. In fact, ARO/CD133pos cells were able to form a higher number of tumor colonies (p = 0.028) (Fig. 4D and 4E).
###end p 52
###begin title 53
Proliferation, self-renewal and colony-forming capacity of ARO/CD133 cells.
###end title 53
###begin p 54
###xml 68 71 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 115 118 115 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 298 301 296 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 345 348 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 499 502 493 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 551 554 545 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 722 725 716 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 735 738 729 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 800 803 794 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 813 816 807 810 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
(A) Cell proliferation assay (MTT). Dotted line represents ARO/CD133neg cells, continuous line represents ARO/CD133pos cells. Data are expressed as mean values+/-SD and are representative of four independent experiments. p<0.03. (B) Cell proliferation assay (BrdU). Dotted line represents ARO/CD133neg cells, continuous line represents ARO/CD133pos cells. Data are expressed as mean values+/-SD and are representative of four independent experiments. p</=0.001. (C) Self-renewal ability of ARO/CD133pos cells. Black line represents number of ARO/CD133pos cells assessed by flow cytometry. Dotted line represents cell viability assessed by MTT assay. (D) Colony formation assay in methylcellulose medium of sorted ARO/CD133pos and CD133neg cells (40x magnification) (E) Number of colonies of ARO/CD133pos and CD133neg cells after 15 days of incubation (p<0.03).
###end p 54
###begin title 55
###xml 22 25 22 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 35 38 35 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
Treatment of ARO/CD133pos and CD133neg cells with chemotherapy drugs
###end title 55
###begin p 56
###xml 63 66 63 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 80 83 80 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 274 277 274 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 449 458 445 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g005">Fig. 5A&#8211;F</xref>
###xml 576 579 572 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 606 609 602 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 645 654 641 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g006">Figure 6A</xref>
###xml 770 779 766 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g006">Figure 6B</xref>
Drug sensitivity was evaluated by MTT and BrdU assay. ARO/CD133pos and ARO/CD133neg cells were incubated with different concentrations of doxorubicin, cisplatin and etoposide. ARO/CD133pos cells showed a remarkable drug resistance to the three agents compared with ARO/CD133neg cells during the entire culture period (p</=0.05 for MTT and p</=0.001 for BrdU, respectively). One representative experiment after 48 hours of each treatment is shown in Fig. 5A-F. Consistently with these findings, apoptosis assessed by caspase 3 activity showed a dramatic activation in ARO/CD133neg in comparison to ARO/CD133pos cells at all time points analyzed (Figure 6A, representative of three independent experiments with doxorubicin). Histograms at time point 72 hours are shown in Figure 6B. Similar results were obtained with the other drugs used (data not shown).
###end p 56
###begin title 57
###xml 24 27 24 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 41 44 41 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
Sensitivity of ARO/CD133pos and ARO/CD133neg cells to chemotherapy agents.
###end title 57
###begin p 58
###xml 464 467 446 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 514 517 496 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
(A) MTT analysis after 48 hours of culture in the presence of 0.5, 1, 1.5 and 2 microM doxorubicin (B) after 48 hours in the presence of 5, 10, 15 and 20 microM cisplatin (C) after 48 hours in the presence of 10, 30 and 100 microM etoposide. Data are expressed as mean values+/-SD and are representative of three independent experiments (p</=0.05). (D) (E) (F) represent BrdU analysis in the same conditions of A, B, C (p</=0.001). Dotted line represents ARO/CD133neg cells and continuous line represents ARO/CD133pos cells in all graphs.
###end p 58
###begin title 59
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
Flow cytometry analysis of caspase 3 in ARO/CD133pos and ARO/CD133neg cells after treatment with chemotherapy agents.
###end title 59
###begin p 60
###xml 89 92 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
(A) Caspase 3 activity after treatment with doxorubicin. Dotted line represents ARO/CD133neg cells, continuous line represents ARO/CD133pos cells. Data are expressed as mean+/-SD (p</=0.001). (B) Caspase 3 activity at time point 72 hours with doxorubicin. Black line represents positive staining for caspase 3, grey line shows negative control with matched isotype antibody. Data are representative of three independent experiments.
###end p 60
###begin title 61
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 38 41 38 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
In vitro characterization of ARO/CD133pos cells
###end title 61
###begin p 62
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 195 198 195 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 241 244 241 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 313 320 313 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g007">Fig. 7A</xref>
###xml 364 367 362 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 374 376 372 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 398 401 394 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 461 464 457 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 472 481 468 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g007">Figure 7B</xref>
###xml 579 588 575 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g007">Figure 7C</xref>
###xml 685 688 681 684 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 734 737 730 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 743 745 739 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
In order to further characterize the ARO/CD133pos population, we evaluated the co-expression of other stem cell markers. The mRNA expression of thyroid transcription factor-1 (TTF-1) in ARO/CD133pos was significantly higher than in ARO/CD133neg cells, similar to TAD-2 fetal thyroid cell line (positive control) (Fig. 7A). OCT-4 expression was 91+/-3% in ARO/CD133pos cells vs 5+/-1.5% in ARO/CD133neg, suggesting the pluripotent stem cell features of ARO/CD133pos cells (Figure 7B). These data were confirmed by semiquantitative PCR, using nTERA2 cell line as positive control (Figure 7C). Quantification, expressed as relative to nTERA2 density, showed OCT-4 mRNA levels in ARO/CD133neg cells almost two fold lower than in ARO/CD133pos (35% vs 62% respectively, with nTERA2 = 100%).
###end p 62
###begin title 63
###xml 42 45 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
Expression of TTF-1 and OCT-4 in ARO/CD133pos and ARO/CD133neg cells.
###end title 63
###begin p 64
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 169 172 169 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 186 189 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 367 370 367 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 384 387 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
(A) qRT-PCR of TTF-1 mRNA expression in ARO/CD133pos and CD133neg cells; TAD-2 cell line was used as positive control. (B) Flow cytometry analysis of OCT-4A in ARO/CD133pos and ARO/CD133neg cells. Black line represents positive staining for OCT-4A, grey line shows negative control with matched isotype antibody. (C) Semiquantitative RT-PCR of OCT-4 mRNA in ARO/CD133pos and ARO/CD133neg cells. beta-actin was used as internal control. nTERA2 cell line was used as positive control. Data are representative of three independent experiments.
###end p 64
###begin p 65
The membrane stem cell markers c-Kit - expressed in ESCs (embryonic stem cells) - and THY-1 - typical of mesenchymal and hematopoietic stem cells - were negative (data not shown).
###end p 65
###begin title 66
Discussion
###end title 66
###begin p 67
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Ailles1">[29]</xref>
###xml 328 332 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Cho1">[30]</xref>
###xml 550 553 550 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Reya1">[5]</xref>
###xml 555 559 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Clarke1">[31]</xref>
###xml 761 765 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Dalerba1">[32]</xref>
In the last few years several studies have been published supporting the hypothesis that tumors arise from heterogeneous cell populations with different biological properties. Recently, it has been suggested that stem cells, characterized by self-renewal and differentiation ability, may play a role in cancer development [29], [30]. Since multiple mutations occurring over many years are necessary before a cell becomes cancerous, stem cells with a long life-span may be the best candidates for accumulating such cancer-inducing heterogeneous cells [5], [31]. However, it is not clear yet whether or not these CSCs originate from dedifferentiation of mature cells within the organs or from resident stem cells which progressively acquire a malignant phenotype [32].
###end p 67
###begin p 68
###xml 101 104 101 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-1">[1]</xref>
###xml 233 236 233 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Lin1">[4]</xref>
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Takano1">[17]</xref>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Takano2">[26]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Takano3">[33]</xref>
###xml 984 987 984 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 994 997 994 997 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 1141 1145 1141 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Mitsutake1">[16]</xref>
###xml 935 940 <span type="species:ncbi:9606">human</span>
###xml 1045 1054 <span type="species:ncbi:10090">nude mice</span>
ATC is one of the most aggressive endocrine tumors characterized by high degree of dedifferentiation [1]. The existence of resident thyroid stem cells may account for both the sustained proliferation and heterogeneity of ATC lesions [4]. Takano et al. hypothesized that a close relationship between stem cells and carcinogenesis might exist in ATC [17], [26], [33]. ATC gene expression profile suggested at least three types of undifferentiated cells as its origin: thyroid stem cells, expressing onfFN mRNA but not Tg, with high differentiation potential, self-renewal and ability to generate anaplastic carcinomas; thyroblasts, expressing both Tg and onfFN mRNA and not forming follicles; prothyrocytes, which are more differentiated than thyroblasts, expressing Tg but not onfFN mRNA, with the ability to form follicles. Mitsutake et al. have identified a very small side population (SP), highly enriched for stem cells, in several human thyroid cancer cell lines. However, both SPpos and SPneg populations formed tumors when transplanted in nude mice, demonstrating that cancer stem-like cells are not exclusive or identical to SP cells [16].
###end p 68
###begin p 69
###xml 109 112 109 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 298 301 298 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 345 352 341 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g001">Fig. 1A</xref>
###xml 500 503 496 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 510 514 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Ma2">[34]</xref>
###xml 816 820 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Takano1">[17]</xref>
In the present study, we ourselves maintain that ATC may originate from thyroid stem cells. We describe CD133pos cells with phenotypical characteristics of stem cells, growing without forming follicles. However, among the four cell lines analyzed, only ARO and KAT-4 showed high percentage of CD133pos cells (64+/-9% and 57+/-12%, respectively; Fig. 1A). Our results are consistent with recent observations on highly aggressive hepatoma cell lines, also characterized by very high percentage of CD133pos cells [34]. High CD133 expression in ATC might be therefore associated with tumor aggressiveness. However, the absence of this marker in KAT-18 and FRO cell lines, suggests that the mere presence of CD133 is not sufficient and other markers still need to be identified. In addition, as reported by Takano et al. [17], we found that ARO and KAT-4 cell lines expressed onfFN but not Tg, TPO and NIS, confirming their undifferentiated status.
###end p 69
###begin p 70
###xml 120 123 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 140 143 140 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 210 213 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 221 234 221 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g004">Fig. 4A and B</xref>
###xml 287 290 287 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 448 451 448 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 461 464 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
To better characterize the functional and phenotypic features of these putative CSCs in ATC, we studied sorted ARO/CD133pos cells. ARO/CD133pos cells showed higher cell proliferation rate in comparison to CD133neg cells (Fig. 4A and B). Furthermore, the self-renewal ability of ARO/CD133pos cells was confirmed by decrease in CD133 expression parallel to increase in cell proliferation, thus suggesting asymmetric division, i.e. production of CD133pos and CD133neg daughter cells. However, mechanisms other than asymmetric division (e.g. CD133 post-transcriptional down-regulation) cannot be excluded. Minimal cell death percentages exclude that the decrease in CD133 expression was due to apoptosis (<2%).
###end p 70
###begin p 71
###xml 47 50 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Nichols1">[22]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Zangrossi1">[23]</xref>
###xml 461 464 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 538 541 538 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Liedtke1">[24]</xref>
Further confirmation that most of the ARO/CD133pos cells may be stem/progenitor cells comes from expression analysis of other genes related to "stemness". Although the stem cell markers c-Kit and THY-1 were negative, a strong positivity was found for OCT-4. OCT-4 belongs to the POU (Pit-Oct-Unc) family of transcription factors which mediates pluripotency in ESCs through the inhibition of tissue-specific and promotion of stem-cell genes [22], [23]. ARO/CD133pos sorted cells were strongly positive for OCT-4A in comparison to ARO/CD133neg cells, and their expression was similar to that of nTERA2 embryonic teratoma cell line. The primers and the monoclonal antibody used in our experiments for the nuclear splicing variant OCT-4A exclude any pseudogene contamination or artifacts [24].
###end p 71
###begin p 72
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Ordonez1">[35]</xref>
###xml 309 312 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 330 333 330 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 597 600 597 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
The nuclear thyroid specific transcription factor TTF-1 is a homeodomain-containing protein belonging to the Nkx-2 class of homeobox genes, which is required for proper thyroid development and is used as a marker of thyroid and lung carcinoma [35]. TTF-1 expression was found significantly higher in ARO/CD133pos than in ARO/CD133neg cells, with mRNA levels comparable to TAD-2 fetal thyroid cell line (positive control). This implies that although all ATC cell lines are dedifferentiated (absent expression of thyroid-specific genes such as Tg, TPO and NIS and positivity for onfFN), in ARO/CD133poscells a marker of thyroid organogenesis is still maintained.
###end p 72
###begin p 73
###xml 445 449 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Alderden1">[36]</xref>
###xml 450 454 450 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Michael1">[38]</xref>
###xml 465 468 465 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 572 575 572 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 658 664 658 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003544-g006">Fig. 6</xref>
###xml 892 896 892 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Giordano1">[39]</xref>
###xml 1086 1089 1086 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 1210 1214 1210 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Liu2">[40]</xref>
Furthermore, in order to functionally characterize these putative cancer stem-like cells, we tested sensitivity to the most common chemotherapy drugs used in ATC, i.e. cisplatin, doxorubicin and etoposide. Cisplatin crosslinks DNA in several different ways interfering with cell division by mitosis, doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis and etoposide inhibits the enzyme Topoisomerase II [36]-[38]. ARO/CD133pos cells revealed a significant resistance to all drugs used at each time point in comparison to ARO/CD133neg cells, as demonstrated by markedly lower apoptosis levels detected via caspase 3 (Fig. 6). The potential induction of antiapoptotic rather than apoptotic molecules, or the blockage of thyrocyte physiological cell-turnover regulatory mechanisms, demonstrated in other thyroid diseases, such as autoimmune thyroiditis [39], might explain the acquired capability of thyroid stem-like cells to become resistant to chemotherapy. As shown in glioblastomas, a better comprehension of the mechanisms allowing ARO/CD133pos cells to resist conventional therapies may help to find ways to manipulate them to become sensitive to these properties [40].
###end p 73
###begin p 74
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Thomas2">[41]</xref>
###xml 168 173 <span type="species:ncbi:9606">human</span>
Our study suggests the existence of cancer stem-like cells in ATCs. However, because there is no unanimous consent about the existence of thyroid stem cells or CSCs in human thyroid, the precise nature of such cells still remains to be established [41].
###end p 74
###begin p 75
###xml 16 20 16 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Schweppe1">[42]</xref>
Schweppe et al. [42] recently questioned the use of thyroid cell lines for identification of molecular aspects involved in carcinogenesis and particularly of ARO 81-1 and KAT-4 cell lines. However, ARO and KAT-4 cell lines used in our experiments, expressed thyroid specific factors TTF-1 and onfFN, confirming their thyroid origin. In addition, PAX8 was also positive (data not shown).
###end p 75
###begin p 76
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003544-Shmelkov1">[43]</xref>
###xml 301 304 301 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neg</sup>
###xml 434 437 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 982 989 982 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 61 70 <span type="species:ncbi:10090">nude mice</span>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 225 230 <span type="species:ncbi:10090">mouse</span>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
###xml 451 456 <span type="species:ncbi:9606">human</span>
A conclusive answer might derive from in vivo experiments in nude mice. However xenograft transplantation by itself may fail to identify true cancer initiating human cells that are not conducive to growth in a non-permissive mouse microenvironment, as recently suggested by Shmelkov et al. [43]. CD133neg cells from metastatic colon cancer were shown to initiate tumors when injected in NOD/SCID mice, challenging the dogma that CD133pos derived from human colon carcinomas are the only cells that could initiate tumor in xenograft models. Indeed, the existence of a high heterogeneity of tumorigenic factors could explain the negativity of KAT-18 and FRO cell lines for CD133. Nevertheless, our preliminary data with immunohistochemical analysis in 5 ATC specimens showed variable positivity for CD133 in all the samples analyzed (personal observations, not published). These results warrant further investigation on large numbers to definitely confirm CD133 expression in all ATC ex vivo specimens.
###end p 76
###begin p 77
In conclusion, our study may contribute to the elucidation of thyroid carcinogenetic mechanisms in ATC, providing new insights for novel therapeutic approaches.
###end p 77
###begin title 78
References
###end title 78
###begin article-title 79
AACE/AME Task Force on Thyroid Nodules American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules.
###end article-title 79
###begin article-title 80
###xml 91 96 <span type="species:ncbi:9606">human</span>
Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid.
###end article-title 80
###begin article-title 81
New type of POU domain in germ line-specific protein OCT-4.
###end article-title 81
###begin article-title 82
New insights into Thyroid Stem cells.
###end article-title 82
###begin article-title 83
Stem cells, cancer, and cancer stem cells.
###end article-title 83
###begin article-title 84
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.
###end article-title 84
###begin article-title 85
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human brain tumor initiating cells.
###end article-title 85
###begin article-title 86
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Isolation and in vitro propagation of tumorigenic breast cancer stem cells with stem/progenitor cell properties.
###end article-title 86
###begin article-title 87
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 59 64 <span type="species:ncbi:9606">human</span>
Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.
###end article-title 87
###begin article-title 88
Gastric cancer originating from bone marrow-derived cells.
###end article-title 88
###begin article-title 89
Identification of bronchioalveolar stem cells in normal lung and lung cancer.
###end article-title 89
###begin article-title 90
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
A human colon cancer cell capable of initiating tumor growth in immunodeficient mice.
###end article-title 90
###begin article-title 91
Opinion: the origin of the cancer stem cell: current controversies and new insights.
###end article-title 91
###begin article-title 92
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
###end article-title 92
###begin article-title 93
Tumor stem cell niches: a new functional framework for the action of anticancer drugs.
###end article-title 93
###begin article-title 94
Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively.
###end article-title 94
###begin article-title 95
Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma.
###end article-title 95
###begin article-title 96
###xml 26 31 <span type="species:ncbi:9606">human</span>
AC133, a novel marker for human hematopoietic stem and progenitor cells.
###end article-title 96
###begin article-title 97
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human embryonic and neuronal stem markers in retinoblastoma.
###end article-title 98
###begin article-title 99
CD133: molecule of the moment.
###end article-title 99
###begin article-title 100
Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4.
###end article-title 100
###begin article-title 101
###xml 26 31 <span type="species:ncbi:9606">human</span>
OCT-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker.
###end article-title 101
###begin article-title 102
Oct4 and its pseudogenes confuse stem cell research.
###end article-title 102
###begin article-title 103
###xml 20 25 <span type="species:ncbi:9606">human</span>
Primary bioassay of human tumor stem cells.
###end article-title 103
###begin article-title 104
Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma.
###end article-title 104
###begin article-title 105
Suppression of BRAF/MEK/MAP kinase restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
###end article-title 105
###begin article-title 106
qBase relative quantification framework and software for management and automated analysis for real-time quantitative PCR data.
###end article-title 106
###begin article-title 107
Cancer stem cells in solid tumors.
###end article-title 107
###begin article-title 108
Recent advances in cancer stem cells.
###end article-title 108
###begin article-title 109
Stem cells and cancer: two faces of eve.
###end article-title 109
###begin article-title 110
Cancer stem cells: models and concepts.
###end article-title 110
###begin article-title 111
Fetal cell carcinogenesis of the thyroid: theory and practice.
###end article-title 111
###begin article-title 112
Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
###end article-title 112
###begin article-title 113
Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas.
###end article-title 113
###begin article-title 114
The discovery and development of cisplatin.
###end article-title 114
###begin article-title 115
Effect of Adriamycin on DNA, RNA and Protein Synthesis in Cell-Free Systems and Intact Cells.
###end article-title 115
###begin article-title 116
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy.
###end article-title 116
###begin article-title 117
Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis.
###end article-title 117
###begin article-title 118
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
###end article-title 118
###begin article-title 119
Thyroid stem cells: lessons from normal development and thyroid cancer.
###end article-title 119
###begin article-title 120
###xml 29 34 <span type="species:ncbi:9606">human</span>
DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
###end article-title 120
###begin article-title 121
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.
###end article-title 121
###begin p 122
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 122
###begin p 123
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was partly supported by grants from the Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) 60% (C.G.)
###end p 123

